Skip to main content
MyDeficiencies

Dexamethasone

Glucocorticoid

Also sold as Decadron.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Dexamethasone has a real, drug-specific nutrient and physiological-category footprint, but it is narrower and more bidirectional than popular "steroid depletion" lists suggest. Its own label states plainly that corticosteroids as a class, dexamethasone included, increase calcium and potassium excretion and decrease intestinal calcium absorption and bone formation; a randomized trial and a longitudinal cohort in dexamethasone-treated preterm infants directly measured disturbed calcium, phosphorus and bone-turnover markers, though in the opposite direction from the adult mechanism in one of those studies, which is disclosed below as genuine counter-evidence. Because dexamethasone is a moderate CYP3A4 inducer, is itself metabolized by CYP3A4, and is nearly devoid of mineralocorticoid activity (StatPearls explicitly notes "very little if any"), its sodium-retention and potassium-wasting risk is real but bounded, and much smaller than for hydrocortisone or fludrocortisone.

Systemic corticosteroid (glucocorticoid) · ATC H02AB02 · also sold as Decadron (legacy); primarily generic · reviewed 2026-09-23. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Dexamethasone in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: ≥2 independent Tier A sources, this drug in the cohort, nutrient directly measured, consistent direction, clinically meaningful magnitude, named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: ≥1 Tier A source with this drug in the cohort showing a real deficit, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating deficit.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence to support even yellow, and no circulating claim to rebut as white. A disclosed absence of evidence, never reworded as reassurance.

What the research found

Calcium

Orange — Moderate

See study details

Dexamethasone reduces intestinal calcium absorption and increases renal calcium excretion; the clearest direct human measurement is in dexamethasone-treated preterm infants, and the direction there was mixed.

Full detail, limits and 2 references

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real deficit, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null finding: Weiler et al. found dexamethasone-treated preterm infants had significantly lower urinary calcium excretion than controls, the opposite of the adult mechanism described in the label, alongside lower plasma phosphorus. This is a genuine, disclosed counter-finding in a specific neonatal population, not a confirmation of the adult mechanism.
  • At-risk subgroups: Postmenopausal women and other populations at baseline osteoporosis risk (per label); preterm infants receiving postnatal dexamethasone for chronic lung disease (per Lin/Weiler cohorts), where the direction of calcium handling differs from the adult mechanism.
  • Counter-evidence on record: See above; direction is population-dependent and this is disclosed rather than smoothed over.

Regulatory status

FDA label (DailyMed): "All corticosteroids increase calcium excretion" and corticosteroids "decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion)." Postmenopausal women are named as an at-risk subgroup.

Population evidence

Lin YJ et al. 1998, PMID 9825973: double-blind trial of early postnatal dexamethasone in 49 preterm infants with respiratory distress syndrome (24 placebo, 25 treated), examining calcium homeostasis and bone growth. Weiler HA et al. 1997, PMID 9088794: longitudinal cohort of dexamethasone-treated preterm infants with chronic lung disease, directly measuring plasma phosphorus and urinary calcium/bone-turnover markers.

Mechanism

Named: glucocorticoid suppression of intestinal calcium absorption (via reduced calcium-transporter activity) plus increased renal calcium excretion and direct inhibition of osteoblast-mediated bone formation, per the regulatory label.

Counter-evidence held on record

Fracture or low bone mineral density is a clinical outcome, not itself proof of calcium deficiency, and is not claimed here as such (Hard Rule 2). The neonatal counter-finding means this entry should not be read as a uniform "dexamethasone always increases calcium loss" claim.

Potassium

Orange — Moderate

See study details

Corticosteroids, dexamethasone included, increase potassium excretion at "average and large doses," per the label, but dexamethasone's own near-absent mineralocorticoid activity meaningfully bounds this risk.

Full detail and limits

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real deficit, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null finding: StatPearls' direct statement that dexamethasone has minimal mineralocorticoid activity is itself a mitigating, drug-specific fact that argues against a large intrinsic kaliuretic effect at typical doses.
  • At-risk subgroups: Patients on concurrent diuretics, amphotericin B, or digitalis glycosides; high-dose or prolonged courses.
  • Counter-evidence on record: Minimal intrinsic mineralocorticoid activity (see above); no isolated dexamethasone-monotherapy hypokalemia incidence study was found to quantify magnitude.

Regulatory status

FDA label (DailyMed): "Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium." Patients should be observed closely for hypokalemia when combined with potassium-depleting agents (amphotericin B, diuretics); increased arrhythmia risk with digitalis glycosides due to hypokalemia.

Population evidence

Class-level label statement applying to dexamethasone; no dexamethasone-specific quantified human trial of potassium loss (as distinct from the label's qualitative warning) was located in this review.

Mechanism

Named, but bounded: residual mineralocorticoid (aldosterone-receptor) activity driving renal potassium wasting, which StatPearls explicitly describes as "very little if any" for dexamethasone specifically, compared with hydrocortisone.

Counter-evidence held on record

This is a wasting/loss-direction risk that is real but drug-specific chemistry meaningfully bounds its size; it should not be extrapolated to the magnitude seen with fludrocortisone or hydrocortisone.

Phosphorus

Orange — Moderate

See study details

Dexamethasone-treated preterm infants had significantly lower plasma phosphorus than controls in a longitudinal cohort.

Full detail, limits and 1 references

What the grade means here: moderate: ≥1 Tier A source with this drug in the cohort showing a real deficit, but bounded by exposure window, subgroup, frequency, or a functional rather than circulating deficit. Orange

Limits on what this shows

  • Key negative/null finding: None located specific to phosphorus; the direction is consistent across the measured bone-turnover markers within this single cohort.
  • At-risk subgroups: Preterm infants receiving postnatal dexamethasone for chronic lung disease/bronchopulmonary dysplasia.
  • Counter-evidence on record: Single cohort; not replicated in an independent Tier A source in this review, and not established in adult populations.

Regulatory status

Not separately addressed in the FDA label; this entry rests on primary literature.

Population evidence

Weiler HA et al. 1997, PMID 9088794: longitudinal cohort of prematurely born infants treated for chronic lung disease with dexamethasone; dexamethasone infants had significantly lower plasma phosphorus alongside lower urinary calcium, pyridinoline and N-telopeptide excretion, indicating compromised bone mineral accretion in this population.

Mechanism

Proposed but not fully elaborated in the available source: disturbed calcium-phosphorus-bone axis regulation during a period of active skeletal mineralization in glucocorticoid-exposed preterm infants.

Counter-evidence held on record

This finding is specific to a neonatal, actively-mineralizing population and should not be generalized to adult dexamethasone courses without direct evidence.

Sodium

Yellow — Low

See study details

The corticosteroid class label warns of sodium and water retention at average/large doses, but dexamethasone "almost completely lacks" the sodium-retaining property of hydrocortisone.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: The drug's own comparative pharmacology data (near-absent mineralocorticoid activity) is the main mitigating counter-evidence.
  • At-risk subgroups: High-dose or prolonged courses; patients with heart failure or hypertension where even modest retention matters clinically.
  • Counter-evidence on record: See mechanism/null finding above.

Regulatory status

FDA label: "average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention"; separately, "at equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives."

Population evidence

Class-level regulatory statement; no dexamethasone-specific quantified sodium-retention trial located.

Mechanism

Residual mineralocorticoid receptor activity, explicitly described as minimal for dexamethasone (StatPearls, DailyMed).

Counter-evidence held on record

This is a retention/excess-direction effect, not a deficiency. Nothing here supports sodium supplementation; if anything, blood-pressure and fluid-status monitoring, not sodium repletion, is the relevant clinical response at high doses (Hard Rule 5).

Vitamin D

Yellow — Low

See study details

Glucocorticoids are mechanistically linked to reduced calcium absorption (a vitamin D-adjacent pathway) and, in separate in vitro work, to induction of the vitamin D-catabolizing enzyme CYP24A1, but the specific glucocorticoid used in the CYP24A1 studies could not be confirmed as dexamethasone during this review.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: None located; this entry's main limitation is unconfirmed drug identity in the primary catabolism sources, not a null result.
  • At-risk subgroups: Patients on chronic dexamethasone with pre-existing low vitamin D status or osteoporosis risk factors.
  • Counter-evidence on record: None located.

Regulatory status

Not addressed directly for vitamin D in the dexamethasone label; the label's calcium-absorption statement is the closest regulatory anchor.

Population evidence

Zayny et al. 2019, PMID 31352041: Saos-2 cells and primary human osteoblasts, effects of glucocorticoids on CYP24A1. Lisakovska O et al. 2023, PMID 37020845: "GC loading depleted the circulating pool of 25OHD3." Neither abstract's exact glucocorticoid identity could be confirmed as dexamethasone specifically during this review (see access note).

Mechanism

Named but unconfirmed for this specific drug: induction of CYP24A1 (25-hydroxyvitamin D/1,25-dihydroxyvitamin D 24-hydroxylase), which catabolizes active and precursor vitamin D metabolites.

Counter-evidence held on record

Graded yellow on class-level/mechanistic grounds and the related calcium-absorption mechanism, not on a confirmed dexamethasone-specific vitamin D catabolism study. A revision should re-verify drug identity in the CYP24A1 literature before any upgrade.

Zinc

Yellow — Low

See study details

A 1981 human study directly measured plasma zinc in subjects given dexamethasone or methylprednisolone; repeated access blocks during this review prevented confirming the exact quantitative direction from the primary source.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: Not determinable; full-text/abstract access to this 1981 paper was blocked (CAPTCHA/bot-verification) on every attempt during this review.
  • At-risk subgroups: Not determinable from available access.
  • Counter-evidence on record: None located; this is an access gap, not a negative finding.

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Yunice AA et al. 1981, PMID 7325187, "Influence of synthetic corticosteroids on plasma zinc and copper levels in humans," examined dexamethasone and methylprednisolone effects on plasma zinc and copper.

Mechanism

Not independently established beyond the general acute-phase/hepatic redistribution pattern seen with copper (see Copper entry); glucocorticoids are known to alter hepatic trace-metal binding-protein synthesis.

Counter-evidence held on record

Graded yellow rather than orange because, although a directly relevant human dexamethasone study exists, this review could not verify its effect size or direction from primary text; do not present this as a confirmed deficiency until the source is re-opened and confirmed.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

Dexamethasone impairs mitochondrial performance across human trabecular meshwork cells, rat liver and brain mitochondria, and mouse myotubes.

Full detail, limits and 3 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: None located; direction is consistent across all dexamethasone-specific sources found.
  • At-risk subgroups: Not established at the human population level; all consistent-direction evidence is cell-culture or animal.
  • Counter-evidence on record: None located in this review; a targeted search for null mitochondrial findings did not return contradicting dexamethasone-specific results.

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Kennedy et al. 2024, PMID 39329939: "Dexamethasone Impairs ATP Production and Mitochondrial Performance in Human Trabecular Meshwork Cells" (human cell culture). Roussel D et al. 2004, PMID 15175015: kinetics and control of oxidative phosphorylation altered in rat liver mitochondria after dexamethasone treatment. Morin C et al. 2000, PMID 11129090: low glucocorticoid concentrations decrease oxidative phosphorylation of isolated rat brain mitochondria. Klein AJ et al. 2026, Biochimie 246:138-144: dexamethasone- and rapamycin-mediated mitochondrial dysfunction in C2C12 myotubes (PMID/DOI not confirmed during this review, see source note).

Mechanism

Named: glucocorticoid receptor-mediated impairment of mitochondrial oxidative phosphorylation kinetics and membrane function, demonstrated directly with dexamethasone in isolated mitochondria and cultured cells across three tissue types.

Counter-evidence held on record

Mechanistic and cell/animal evidence only; no human clinical mitochondrial-function study in dexamethasone-treated patients was located, so this stays yellow rather than orange or red. See Overlap map: this entry shares its three strongest sources with ATP production below.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

Multiple dexamethasone-specific animal and cell-culture studies show elevated oxidative-stress markers and reduced antioxidant enzyme activity.

Full detail, limits and 7 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: None located; every dexamethasone-specific source found reports oxidative stress increasing, not decreasing, with treatment.
  • At-risk subgroups: Not established in humans; all consistent-direction evidence is animal or cell-culture.
  • Counter-evidence on record: None located; a dedicated human oxidative-stress search in dexamethasone-treated patients was attempted but blocked by rate limiting before completion (see access note). This gap is disclosed rather than assumed null.

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Ulla A et al. 2021, PMID 33848514 (mouse C2C12 myotubes); Ulla A et al. 2022, PMID 35977398 (female mice); Oh S et al. 2021, PMID 34885708 (dexamethasone-induced muscle atrophy, oxidative stress); Uzochukwu IE et al. 2025, PMID 39919567 (Japanese quail, dexamethasone plus vitamin E/selenium); Bai K et al. 2023, PMID 37302326 (laying hens); Arafa EA et al. 2023, PMID 36889109 (dexamethasone-induced osteoporosis, oxidative role); Wang C et al. 2024, PMID 39154612 (laying hens); Wang K et al. 2026, Free Radic Biol Med 255:930-945 (dexamethasone-induced atrophy, UCP3-associated redox homeostasis, PMID not confirmed).

Mechanism

Named: glucocorticoid receptor-driven increases in reactive oxygen species and reduced superoxide dismutase/catalase activity, with elevated malondialdehyde (lipid peroxidation marker), demonstrated directly with dexamethasone across avian and rodent/cell models.

Counter-evidence held on record

Cell/animal mechanistic evidence only. Several of the animal sources are co-treatment (antioxidant supplementation) studies designed to show protection against dexamethasone's oxidative effect, not natural-history depletion studies; that distinction is preserved here rather than treated as independent confirmation.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

See study details

Rat hepatocyte studies consistently show dexamethasone inducing ceruloplasmin (a copper-transport protein) synthesis, a reverse-direction finding from "depletion," alongside an unconfirmed-direction human measurement.

Full detail, limits and 4 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: No dexamethasone-specific finding of reduced serum copper was located; all dexamethasone-specific mechanistic sources point toward increased ceruloplasmin/copper-protein handling.
  • At-risk subgroups: Not established for humans; mechanism is rodent hepatocyte-derived.
  • Counter-evidence on record: This is itself the counter-evidence against a "dexamethasone depletes copper" claim.

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Yunice AA et al. 1981, PMID 7325187 (human, dexamethasone and methylprednisolone, direction not confirmed from primary text, see Zinc entry). Fitch CA et al. 1999, PMID 10320628 (developmental animal model): ceruloplasmin synthesis enhanced with dexamethasone treatment. Weiner AL & Cousins RJ 1983, PMID 6882374 (rat hepatocyte primary culture): "synthesis and secretion of this protein [ceruloplasmin] was enhanced when cells were treated with dexamethasone." Weiner AL & Cousins RJ 1983, PMID 6889313 (rat hepatocyte primary culture): differential regulation of copper and zinc metabolism with dexamethasone exposure.

Mechanism

Named: glucocorticoid receptor-mediated transcriptional induction of hepatic ceruloplasmin, an acute-phase copper-binding/transport protein.

Counter-evidence held on record

This is a reverse-direction (retention/increased-handling) finding, not a depletion signal. It should not be used to support copper supplementation; the animal mechanism runs the opposite way.

Iron

Yellow — Low

See study details

Dexamethasone-treated rats in liver-injury models show altered iron homeostasis in the direction of overload, not loss.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: No dexamethasone-specific finding of iron loss or anemia mechanism was located in this review.
  • At-risk subgroups: Not established for humans; this is rodent hepatic-injury-model evidence only.
  • Counter-evidence on record: This finding is itself the counter-evidence against a "dexamethasone depletes iron/causes anemia" claim (see also Oxygen delivery/utilization entry).

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Alharbi NS et al. 2026, PMID 41971076, "Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis" (rat model): a comparator drug "restored iron homeostasis and alleviated signs of iron overload" in dexamethasone-treated animals, implying dexamethasone exposure itself produced iron overload in this model. A related 2026 paper by the same group (Ambrisentan, dexamethasone-treated rats) reports a similar hepatic injury model.

Mechanism

Not fully elaborated in the available source; plausibly linked to dexamethasone-induced hepatic steatosis/injury altering hepatic iron handling, rather than a direct iron-transporter effect.

Counter-evidence held on record

Reverse-direction finding: animal evidence points toward iron accumulation associated with dexamethasone-induced liver injury, not iron deficiency. Iron supplementation should not be inferred from this entry; if anything, unexplained iron-overload markers in a dexamethasone-treated patient warrant clinical evaluation, not repletion.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

Dexamethasone exposure alters gut microbiota composition in humanized-microbiome mice and in offspring of prenatally exposed animals.

Full detail, limits and 4 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: None located.
  • At-risk subgroups: Prenatal/perinatal dexamethasone exposure (per Lu et al., offspring effects); no human postnatal at-risk subgroup established.
  • Counter-evidence on record: None located; no human microbiome study in dexamethasone-treated patients was found in this review.

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Green et al. 2024, PMID 38792844: "Exploring Gut Microbiota Alterations with Trimethoprim-Sulfamethoxazole and Dexamethasone in a Humanized Microbiome Mouse Model." Lu et al. 2024, PMID 38301654: "Epigenetic programming mediates abnormal gut microbiota... in offspring with prenatal dexamethasone exposure." Shi et al. 2025, PMID 40522031: dexamethasone-induced muscle growth inhibition mechanisms examined via microbiota. Couch et al. 2023, PMID 36782001: dexamethasone slow-release implants altered gut microbiome composition in Chinook salmon (non-mammalian, lower translational relevance, noted as such).

Mechanism

Not fully elaborated at the molecular level in available abstracts; consistent with glucocorticoid-driven changes in gut immune tone, mucus/bile handling and transit affecting resident flora.

Counter-evidence held on record

All dexamethasone-specific evidence is animal; the salmon study in particular has limited relevance to human physiology and is included only as a directionally consistent, disclosed data point, not as independent confirmation.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Yellow — Low

See study details

Glucocorticoid receptor activation is linked to increased erythropoietin expression and red blood cell mass in animal and endogenous-hypercortisolism human data, the opposite of an oxygen-delivery deficit.

Full detail, limits and 3 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: None located specific to dexamethasone reducing hemoglobin/hematocrit or oxygen delivery.
  • At-risk subgroups: Not established for exogenous dexamethasone dosing; the strongest human data (Cushing's) reflects endogenous hypercortisolism.
  • Counter-evidence on record: This entry itself functions as counter-evidence against any "dexamethasone causes anemia/reduced oxygen-carrying capacity" claim; see Fails Verification, which is distinct from this drug's own intended anti-inflammatory/immunosuppressive mechanism (Hard Rule 2 applied: this is not the drug's therapeutic purpose, it is an incidental hematologic effect tied to the same receptor).

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Tang JI et al. 2011, PMID 21540288 (rat offspring): "Prenatal glucocorticoid overexposure causes permanent increases in renal erythropoietin expression and red blood cell mass in the rat offspring" (the specific glucocorticoid used could not be fully confirmed as dexamethasone from the available excerpt; prenatal-glucocorticoid rodent models commonly use dexamethasone or betamethasone, so this is disclosed as unconfirmed drug identity). Varricchio L et al. 2023, PMID 35861015, and Gursoy A et al. 2006, PMID 17033265 (human, Cushing's disease): endogenous hypercortisolism produces erythrocytosis/elevated hemoglobin, a related but distinct mechanism (endogenous cortisol excess, not exogenous dexamethasone dosing) operating through the same glucocorticoid receptor pathway.

Mechanism

Named at the class/pathway level: glucocorticoid receptor stimulation of erythropoietin expression and erythroid progenitor proliferation. Drug-level confirmation for dexamethasone specifically is incomplete (see above).

Counter-evidence held on record

Reverse-direction, mechanism-only finding with incomplete drug-identity confirmation in the strongest animal source. Framed as a caution against "steroids cause anemia/fatigue from low oxygen delivery" narratives, not as a claim that dexamethasone reliably raises red-cell mass in typical clinical dosing.

ATP production

Yellow — Low

See study details

Dexamethasone directly reduces ATP generation in human trabecular meshwork cells and alters oxidative-phosphorylation-linked ATP synthesis kinetics in isolated rat mitochondria.

Full detail, limits and 4 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where at least one class member has real data but this drug does not; also used for context flags and reverse-direction (protective or retention) findings. Yellow

Limits on what this shows

  • Key negative/null finding: None located.
  • At-risk subgroups: Not established at the human population level; strongest evidence is human cell culture (ocular trabecular meshwork) and rodent isolated-mitochondria work, not a clinical cohort.
  • Counter-evidence on record: None located.

Regulatory status

Not addressed in the dexamethasone label.

Population evidence

Kennedy et al. 2024, PMID 39329939: dexamethasone-treated human trabecular meshwork cells showed significantly reduced ATP generation. Graybeal et al. 2022, PMID 34896106: metabolic profile of dexamethasone-treated human trabecular meshwork cells (related glaucoma-model work). Roussel D et al. 2004, PMID 15175015: ATP synthesis contributions altered in rat liver mitochondria after dexamethasone treatment. Morin C et al. 2000, PMID 11129090: decreased oxidative phosphorylation (ATP-generating capacity) in isolated rat brain mitochondria at low glucocorticoid concentrations.

Mechanism

Named: glucocorticoid receptor-mediated impairment of mitochondrial oxidative phosphorylation directly reducing ATP synthesis, demonstrated with dexamethasone in human cells and rodent isolated mitochondria.

Counter-evidence held on record

This entry shares its three strongest sources (Kennedy 2024, Roussel 2004, Morin 2000) with Mitochondrial burden above; see Overlap map. It should not be read as two independent lines of confirmation.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Vitamin C

    Where it comes from: Standard corticosteroid-class "depletion list" repeated across popular drug-nutrient depletion references (this review could not open a live consumer page to trace the exact origin; search engines and named consumer sites returned robots-blocked, site-blocked, or 404 responses during this session, see access note).

    Why it fails: No dexamethasone-specific or class-level Tier B/C evidence of systemic vitamin C depletion was located. The adjacent physiology (ACTH-stimulated adrenal ascorbic acid turnover) runs, if anything, in the opposite direction for a drug that suppresses endogenous ACTH via negative feedback, rather than stimulating it.

  • Chromium

    Where it comes from: Standard corticosteroid-class "depletion list" (same access caveat as above).

    Why it fails: No dexamethasone-specific or class-level Tier B/C evidence was located in PubMed or Europe PMC searches conducted for this review.

  • Vitamin B12 / folate

    Where it comes from: Standard corticosteroid-class "depletion list" (same access caveat as above).

    Why it fails: The only located study combining dexamethasone with folate/homocysteine measurement (Huang Y et al. 2019, PMID 31735046, 52 patients with sudden deafness) used dexamethasone alongside Ginkgo biloba extract and hyperbaric oxygen therapy as a combination protocol, so it cannot isolate a dexamethasone-specific effect on B12, folate, or homocysteine. No other supporting evidence at any tier was found.

  • Selenium

    Where it comes from: Standard corticosteroid-class "depletion list" (same access caveat as above).

    Why it fails: The only dexamethasone-related selenium literature found (Uzochukwu IE et al. 2025, PMID 39919567, Japanese quail) tests selenium/vitamin E supplementation as protection against dexamethasone-induced oxidative stress; it does not measure or demonstrate that dexamethasone lowers selenium status, and cannot support a depletion claim.

  • Magnesium

    Where it comes from: Standard corticosteroid-class "depletion list" (same access caveat as above).

    Why it fails: Searches for dexamethasone and magnesium returned only unrelated co-therapy studies (magnesium sulfate or magnesium-based implants used alongside dexamethasone for other purposes), not depletion-mechanism studies. This search was constrained by repeated rate-limiting across PubMed, Europe PMC, and Semantic Scholar before full multi-phrasing coverage could be completed; it is disclosed as a limited-thoroughness negative result rather than a fully exhausted one, and should be re-checked in a future revision.

All references used above
  1. NCBI Bookshelf, StatPearls, "Dexamethasone" — Reference article; pharmacokinetics (absorption, CYP3A4 metabolism, protein binding, half-life, renal excretion), mineralocorticoid activity, adverse effects.
  2. DailyMed, dexamethasone tablet/oral solution label (setid 537b424a-3e07-4c81-978c-1ad99014032a) — FDA-approved labeling; clinical pharmacology, potassium-depleting agent interaction, digitalis interaction, sodium/water/potassium warnings.
  3. DailyMed, dexamethasone "6-Day" tablet label (setid efaeb61c-ad51-41e7-a2ba-84d8db186ff1) — FDA-approved labeling; calcium excretion/bone formation-resorption statement, CYP3A4 moderate-inducer statement, warfarin and NSAID interactions.
  4. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code H02AB02 — Confirms ATC code H02AB02 = dexamethasone, DDD 1.5 mg, oral/parenteral.
  5. McCune JS et al. 2000. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. — Human volunteers; CYP3A4 induction by dexamethasone. PMID 11061575.
  6. Varis T et al. 2000. Itraconazole markedly increases plasma dexamethasone concentrations. — Human study; itraconazole decreased dexamethasone systemic clearance 68%, increased AUC 3.3-fold. PMID 11103751.
  7. Lin YJ et al. 1998. Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. — Double-blind RCT, 49 preterm infants (24 placebo, 25 treated). PMID 9825973.
  8. Weiler HA et al. 1997. Longitudinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone. — Human cohort; lower plasma phosphorus, lower urinary calcium/pyridinoline/N-telopeptide excretion in dexamethasone-treated infants. PMID 9088794.
  9. Yunice AA et al. 1981. Influence of synthetic corticosteroids on plasma zinc and copper levels in humans. — Human study, dexamethasone and methylprednisolone.Full text/abstract blocked by bot-verification on every access attempt in this review; effect direction not independently confirmed. PMID 7325187.
  10. Fitch CA et al. 1999. Developmental regulation of hepatic ceruloplasmin mRNA and serum activity by exogenous thyroxine and dexamethasone. — Animal/developmental model; dexamethasone enhanced ceruloplasmin synthesis. PMID 10320628.
  11. Weiner AL, Cousins RJ. 1983. Hormonally produced changes in caeruloplasmin synthesis and secretion in primary cultured rat hepatocytes. — Rat hepatocyte culture; dexamethasone increased ceruloplasmin synthesis/secretion. PMID 6882374.
  12. Weiner AL, Cousins RJ. 1983. Differential regulation of copper and zinc metabolism in rat liver parenchymal cells in primary cultures. — Rat hepatocyte culture; dexamethasone-altered metal accumulation patterns. PMID 6889313.
  13. Alharbi NS et al. 2026. Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis. — Rat model; comparator drug restored iron homeostasis and alleviated iron overload in dexamethasone-treated animals. PMID 41971076.
  14. Kennedy et al. 2024. Dexamethasone Impairs ATP Production and Mitochondrial Performance in Human Trabecular Meshwork Cells. — Human cell culture. PMID 39329939.
  15. Graybeal et al. 2022. Metabolic profile of dexamethasone-treated human trabecular meshwork cells. — Human cell culture. PMID 34896106.
  16. Roussel D et al. 2004. Kinetics and control of oxidative phosphorylation in rat liver mitochondria after dexamethasone treatment. — Rat model. PMID 15175015.
  17. Morin C et al. 2000. Low glucocorticoid concentrations decrease oxidative phosphorylation of isolated rat brain mitochondria. — Rat model. PMID 11129090.
  18. Klein AJ et al. 2026. Dexamethasone- and rapamycin-mediated mitochondrial dysfunction occurs independently of altered Yin Yang 1 expression in C2C12 myotubes. Biochimie 246:138-144. — Mouse myotube cell line.PMID/DOI not confirmed; retrieved via Europe PMC listing, direct confirmation blocked by rate limiting during this review.
  19. Ulla A et al. 2021. Morin attenuates dexamethasone-mediated oxidative stress and atrophy. Arch Biochem Biophys. — Mouse C2C12 myotubes. PMID 33848514.
  20. Ulla A et al. 2022. Biosci Biotechnol Biochem. — Female mice; morin modulation of dexamethasone-induced oxidative stress markers. PMID 35977398.
  21. Oh S et al. 2021. Fermented Oyster Extract Attenuated Dexamethasone-Induced Muscle Atrophy by Decreasing Oxidative Stress. Molecules. — Animal model. PMID 34885708.
  22. Uzochukwu IE et al. 2025. Poult Sci. — Japanese quail cocks; vitamin E/selenium vs. dexamethasone-induced oxidative stress. PMID 39919567.
  23. Bai K et al. 2023. Poult Sci. — Laying hens; melatonin effects on dexamethasone-induced oxidative stress. PMID 37302326.
  24. Arafa EA et al. 2023. Biomed Pharmacother. — Diosmin's antioxidant role in dexamethasone-induced osteoporosis. PMID 36889109.
  25. Wang C et al. 2024. Poult Sci. — Laying hens; betaine supplementation under dexamethasone-induced oxidative stress. PMID 39154612.
  26. Wang K et al. 2026. HDAC6 inhibition alleviates dexamethasone-induced skeletal muscle atrophy and enhances UCP3-associated redox homeostasis. Free Radic Biol Med 255:930-945. — Cell/animal model.PMID/DOI not confirmed; retrieved via Europe PMC listing, direct confirmation blocked by rate limiting during this review.
  27. Mitra A et al. 2026. Vitamin B3 rescues mitochondrial homeostasis in dexamethasone-induced skeletal muscle atrophy by reducing oxidative stress. J Bioenerg Biomembr 58(1):6. — Cell/animal model.PMID/DOI not confirmed; retrieved via Europe PMC listing, direct confirmation blocked by rate limiting during this review.
  28. Green et al. 2024. Exploring Gut Microbiota Alterations with Trimethoprim-Sulfamethoxazole and Dexamethasone in a Humanized Microbiome Mouse Model. — Humanized-microbiome mouse model. PMID 38792844.
  29. Lu et al. 2024. Epigenetic programming mediates abnormal gut microbiota in offspring with prenatal dexamethasone exposure. — Rodent offspring model. PMID 38301654.
  30. Shi et al. 2025. Dexamethasone-induced muscle growth inhibition mechanisms via microbiota. — Animal model. PMID 40522031.
  31. Couch et al. 2023. Dexamethasone slow-release implants and gut microbiome composition in Chinook salmon. — Non-mammalian model; lower translational relevance, noted as such in the entry. PMID 36782001.
  32. Tang JI et al. 2011. Prenatal glucocorticoid overexposure causes permanent increases in renal erythropoietin expression and red blood cell mass in the rat offspring. — Rat offspring model.Specific glucocorticoid drug identity not fully confirmed as dexamethasone from the available excerpt; disclosed in the Oxygen delivery/utilization entry. PMID 21540288.
  33. Varricchio L et al. 2023. Hematopoietic progenitor changes and erythrocytosis in Cushing disease. — Human, Cushing disease cohort (endogenous hypercortisolism, not exogenous dexamethasone). PMID 35861015.
  34. Gursoy A et al. 2006. Erythrocytosis and polycythemia as initial manifestations of Cushing's disease. — Human case report (endogenous hypercortisolism). PMID 17033265.
  35. Lisakovska O et al. 2023. Glucocorticoid loading and depletion of circulating 25-hydroxyvitamin D3. — Animal model.Specific glucocorticoid drug identity not confirmed as dexamethasone; full abstract access blocked during this review. PMID 37020845.
  36. Zayny et al. 2019. Effects of glucocorticoids on vitamin D3-metabolizing 24-hydroxylase (CYP24A1). — Saos-2 cells and primary human osteoblasts.Specific glucocorticoid drug identity not confirmed as dexamethasone from the available excerpt. PMID 31352041.
  37. Huang Y et al. 2019. Folic acid and homocysteine in dexamethasone, Ginkgo biloba extract, and hyperbaric oxygen combination therapy for sudden deafness. — Human, 52 patients; combination protocol, cannot isolate dexamethasone-specific effect. PMID 31735046.
  38. Rikans LE. 1986. Drugs and nutrition in old age. Life Sci. — General narrative review naming corticosteroids among drugs posing nutritional hazards in the elderly; not dexamethasone-specific, not drug-level stratified. Tier C/D background only, not used to support any graded claim. PMID 3528728.